argenx SE (1AE.F) Stock Price, News & Chart

	1AE.F	ROIV	9995.HK	095700.KQ	1801.HK	688520.SS
Market cap	51.54B	27.61B	40.23B	94.14B	154.42B	15.35B
P/E (TTM)	33.0	—	6.1	—	116.5	—
Forward P/E	—	-27.5	46.7	—	34.9	21.9
Price/book	6.8	6.5	3.8	—	6.3	-22.6
Dividend yield	—	—	—	—	—	—
1-year change	+10.47%	+85.85%	−19.94%	−60.56%	−3.41%	−37.00%
Today	+2.60%	+6.08%	+1.49%	+0.73%	+4.12%	+1.02%

Market cap

51.54B

27.61B

40.23B

94.14B

154.42B

15.35B

P/E (TTM)

33.0

—

6.1

—

116.5

—

Forward P/E

—

-27.5

46.7

—

34.9

21.9

Price/book

6.8

6.5

3.8

—

6.3

-22.6

Dividend yield

—

1-year change

+10.47%

+85.85%

−19.94%

−60.56%

−3.41%

−37.00%

Today

+2.60%

+6.08%

+1.49%

+0.73%

+4.12%

+1.02%

Company	Mkt cap	Price	Today
Roivant Sciences Ltd.ROIV · Biotechnology	27.61B	38.23	+6.08%
RemeGen Co., Ltd.9995.HK · Biotechnology	40.23B	71.300	+1.49%
Genexine, Inc.095700.KQ · Biotechnology	94.14B	2,070.00	+0.73%
Innovent Biologics, Inc.1801.HK · Biotechnology	154.42B	88.550	+4.12%
Sinocelltech Group Limited688520.SS · Biotechnology	15.35B	32.63	+1.02%
Incyte CorporationINCY · Biotechnology	25.04B	122.85	+4.47%
TG Therapeutics, Inc.TGTX · Biotechnology	9.43B	61.63	+1.45%
Hansa Biopharma AB (publ)24H.F · Biotechnology	352.86M	3.5380	−0.23%

Company	Mkt cap	Price	Today
Pell Bio-Med Technology Co., Ltd.6949.TW · Taipei, Taiwan	50.60B	38.60	−2.15%
Asymchem Laboratories (Tianjin) Co., Ltd.002821.SZ · Tianjin, China	58.44B	161.45	+8.47%
UCB SAUNC.F · Brussels, Belgium	54.28B	284.70	+3.11%
Pharmaron Beijing Co., Ltd.3759.HK · Beijing, China	55.85B	30.400	+3.47%
ALK-Abelló A/SALK-B.CO · Horsholm, Denmark	54.89B	247.40	+1.56%
BioMarin Pharmaceutical Inc.B1MR34.SA · San Rafael, CA	55.80B	144.05	0.00%
CSL LimitedCSJ.F · Melbourne, VIC	59.76B	124.54	+1.83%
Zota Health Care LimitedZOTA.NS · Surat, India	42.21B	1,218.80	+0.07%

Company	Mkt cap	Price	Today
IOL Chemicals and Pharmaceuticals LimitedIOLCP.BO · Drug Manufacturers - Specialty & Generic	55.54B	189.20	+3.08%
Sinopharm Group Co. Ltd.1099.HK · Medical Distribution	52.96B	16.970	+1.74%
Humana Inc.HUM · Healthcare Plans Odds	50.12B	417.42	−0.11%
Pell Bio-Med Technology Co., Ltd.6949.TW · Biotechnology	50.60B	38.60	−2.15%
Senores Pharmaceuticals LimitedSENORES.NS · Drug Manufacturers - General	54.71B	1,187.90	+4.48%
ResMed Inc.RMD.AX · Medical Instruments & Supplies	48.68B	34.61	+3.53%
Bayer AktiengesellschaftBAYA.F · Drug Manufacturers - General	53.84B	13.70	+3.01%
Agilent Technologies, Inc.A · Diagnostics & Research	49.96B	177.17	+0.97%

Company	Mkt cap	Price	Today
Prosus N.V.1TY.F · Amsterdam, Netherlands	81.54B	39.02	+7.21%
ING Groep N.V.ING · Amsterdam, Netherlands	93.30B	32.84	+6.28%
NEPI Rockcastle N.V.0A3.F · Amsterdam, Netherlands	5.57B	7.88	+3.14%
Heineken Holding N.V.4H5.F · Amsterdam, Netherlands	21.79B	79.75	+3.91%
Ferrovial N.V.FER · Amsterdam, Netherlands	42.36B	58.95	+2.45%
ABN AMRO Bank N.V.ABN.AS · Amsterdam, Netherlands	34.13B	41.88	+0.77%
Adyen N.V.1N8.F · Amsterdam, Netherlands	27.86B	882.70	+3.75%
Koninklijke Philips N.V.PHG · Amsterdam, Netherlands	30.36B	31.06	+9.14%

FinancialContent·1d ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

FinancialContent INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on b

ARDX

The Manila Times·2d agoPositive

argenx to Present at Upcoming Investor Conferences

The Manila Times Amsterdam, the Netherlands - argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced that members of the management team will participate in the following investor conferences in November: -…

ARGX ARLSF MS

Pluang·2d agoNegative

argenx to present at two major healthcare investor conferences in November 2026

argenx, an immunology innovation company, announced its management team will participate in two investor conferences in November 2026: the Guggenheim Healthcare Innovation Conference in Boston on November 10 and the Jefferies London Global…

ARGX MS

The Globe and Mail·Oct 28Negative

Analysts Have Conflicting Sentiments on These Healthcare Companies: Molina Healthcare (MOH), Quest Diagnostics (DGX) and Argenx Se (ARGX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Molina Healthcare (MOH), Quest Diagnostics (DGX) and Argenx Se (ARGX). In a report released today, Andrew Mok CFA from Barclays maintained a…

MOH LLY BMY MDGL

The Globe and Mail·Oct 26

Zacks Investment Ideas feature highlights: Cummins, Argenx and PACCAR

Chicago, IL – October 16, 2026– Today, Zacks Investment Ideas feature highlights Cummins CMI, Argenx ARGX and PACCAR PCAR. AI stocks sold off Wednesday and in early morning trading Thursday as investors raced to protect profits. That said,…

NVDA RIVN SPCX BWA

pharmaphorum·Oct 26Negative

argenx's Forte acquisition delivers coeliac trial win

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2 billion acquisition of Forte Biosciences, will move into phase 3 development for coeliac disease after showing efficacy in a mid-stage trial. There are no FDA-approved…

TRAX AES ARGX NVS

24/7 Wall St.·Oct 22

argenx Q3 2026: $1.72B Revenue and Five 2027 Launches Ahead

As seen on the 24/7 Wall St. homepage on October 22, 2026. As many as five new launches are lined up for 2027, spanning pediatric gMG, ocular MG, necrotizing myopathy, the autoinjector and empasiprubart in MMN, on the back of VYVGART…

ARGX LLY PFE SNY

The Killeen Daily Herald·Oct 22·2 outletsPositive

argenx Reports Third Quarter 2026 Financial Results and Provides Business Update

Continued strong VYVGART performance drives $1.7 billion in global product net sales, representing 54% year-over-year growth and 13% quarter-over-quarter growth sBLA for VYVGART Hytrulo in IMNM on track for submission by year-end; pursuing…

ARGX SNY PFE

Argenx outlines 2026 OpEx at ~$4B as it plans up to 5 U.S. launches in 2027

argenx Q3 2026 earnings: VYVGART sales hit $1.7B, 2027 launches loom, but DM and Sjogren risks remain. Earnings Call Insights: argenx (ARGX) Q3 2026 - Karen Massey (CEO & Executive Director) said, "Nearly 5 years into launch, we're still…

ARGX ADRX SNY MS

The Motley Fool·Oct 23·2 outletsPositive

argenx (ARGX) Q3 2026 Earnings Call Transcript

Operator: Good morning. My name is Ryan, and I will be your conference operator today. I would like to welcome everyone to the call. [Operator Instructions] Thank you. I'd like to introduce Beth DelGiacco, Vice President of Corporate…

ARGX MS BCS

Install

argenx SE

Key statistics

Against its peers

Latest news